Connect with us

Health

Depression could be 'zapped' away with brain stimulation, new study suggests: ‘Better quality of life’

Published

on

Depression could be 'zapped' away with brain stimulation, new study suggests: ‘Better quality of life’

Join Fox News for access to this content

Plus get unlimited access to thousands of articles, videos and more with your free account!

Please enter a valid email address.

By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your email and follow the instructions provided.

For those with severe depression, relief could soon be just an MRI away.

In a major clinical trial, researchers from the University of Nottingham in the U.K. applied transcranial magnetic stimulation (TMS) to the brains of 255 patients with treatment-resistant depression over a total of 20 sessions.

Advertisement

The patients reported “substantial improvements” in their symptoms and quality of life for at least six months after the procedure, according to a press release from the university.

MENTAL HEALTH MAY BE WORSE IN TEENS FROM LARGE FAMILIES, STUDY SUGGESTS: ‘FEWER RESOURCES’

More than two-thirds of participants responded to the treatment, with a third showing 50% improvement in symptoms. 

For one-fifth of the patients, their depression did not return.

Researchers from the University of Nottingham applied transcranial magnetic stimulation to the brains of 255 patients with treatment-resistant depression over a total of 20 sessions. (iStock)

Advertisement

“Given that these patients are people who have not responded to two previous treatment attempts and have been ill for an average of seven years, to get such a significant response rate and a fifth who have a sustained response is really encouraging,” lead researcher Richard Morriss, professor of psychiatry at the University of Nottingham, told Fox News Digital, said in the release.

The findings were published in the journal Nature Medicine on Jan. 16. 

JEWISH STUDENTS STRUGGLING WITH ANTISEMITISM AT COLLEGE NOW HAVE USE OF WALK-IN MENTAL HEALTH CLINIC

“Transcranial magnetic stimulation is a well-established treatment for depression that is available in many but not all centers, unlike antidepressants, ECT and psychological treatments, which are available anywhere,” Morriss told Fox News Digital.

Previously, TMS has been delivered in a less effective and precise way, Morriss said, and the results didn’t last as long.

Advertisement

The patients reported “substantial improvements” in their symptoms and quality of life for at least six months after the procedure, said researchers. (iStock)

“The importance of this research is that for the first time, in a large enough randomized controlled trial, the benefits on depression lasted six months or more,” he said.

“Not only that, but on average, one in two people [who received] the TMS had a substantial benefit in depression lasting at least six months — enough to improve their anxiety and make them think clearly, function better and have a better quality of life.”

“The benefits to people who have suffered for years are quite remarkable.”

The researchers used an MRI scan to personalize the site of the magnetic stimulation for each patient, Morriss noted.

Advertisement

“We used a neuronavigation system, or tracking system, to ensure that the same site was hit for all 20 TMS sessions, [even] if the person sat in a slightly different position or moved slightly,” he said.

Ninety-two percent of the study participants completed the full treatment, said Morriss, with only “minor side effects” that lasted less than a day.

In 2023, 29% of Americans reported having been diagnosed with depression at some point in their lives, while 17.8% said they currently suffer from it. (iStock)

“People went to the hospital and could resume their usual activities, and they could drive there and back for this treatment,” he said.

Although the MRI-guided treatment costs about 25% more than the traditional TMS treatments, Morriss said the benefits last longer — “so maybe the person only needs one or at the most two courses of treatment per year.”

Advertisement

DEPRESSION AND ANXIETY RATES HIGHER AMONG COLLEGE STUDENTS THAN THEIR PEERS, NEW STUDY SUGGESTS

The study did have some limitations, Morriss acknowledged.

The researchers were not able to include a placebo group, as it was deemed “ethically and clinically unacceptable” to give a placebo treatment for as long as six months to such a seriously ill group of people, he said. 

Although the MRI-guided treatment costs about 25% more than the traditional TMS treatments, the benefits last longer, researchers said. (iStock)

“So we do not know for sure how much of the TMS effect is real and how much is due to other factors,” he noted. “It seems likely that a high proportion of the effect is due to TMS.”

Advertisement

Not every center offering TMS can access MRI technology, Morriss said, but many sites across the U.S. and Canada do have the equipment. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“The additional cost and lack of availability of MRI or the expertise to use it is something that doctors and insurers will need to consider,” he added.

Alex Dimitriu, M.D., a psychiatrist and founder of Menlo Park Psychiatry & Sleep Medicine in California, was not involved in the Nottingham study but reviewed the findings.

“There is no doubt that magnetic brain stimulation can be an effective treatment for depression, and this study, using targeted magnetic pulses, further reinforces the efficacy of this treatment,” a psychologist said.  (iStock)

Advertisement

“There is no doubt that magnetic brain stimulation can be an effective treatment for depression, and this study, using targeted magnetic pulses, further reinforces the efficacy of this treatment,” he said. 

A similar type of focused magnetic therapy was developed at Stanford, which found similar strong positive outcomes, Dimitriu said. 

“Notably, these therapies can be expensive and somewhat time-consuming — however, the benefits to people who have suffered for years are quite remarkable,” he said. 

For anyone dealing with a treatment-resistant psychiatric condition, Dimitriu emphasized the importance of correcting and optimizing sleep before gauging the effectiveness of any treatment.

Advertisement

In 2023, 29% of Americans reported having been diagnosed with depression at some point in their lives, while 17.8% said they currently suffer from it.

For more Health articles, visit www.foxnews.com/health.

Health

Why Weight Loss Efforts Can Sometimes Lead to Constipation and Digestive Changes

Published

on

Why Weight Loss Efforts Can Sometimes Lead to Constipation and Digestive Changes


Advertisement





Why Weight Loss Efforts Can Sometimes Lead to Constipation




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Could cancer vaccines be next? New treatment cuts melanoma risk by nearly 50%

Published

on

Could cancer vaccines be next? New treatment cuts melanoma risk by nearly 50%

NEWYou can now listen to Fox News articles!

A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period.

The personalized mRNA cancer therapy, called intismeran autogene, combined with the cancer immunotherapy drug KEYTRUDA (pembrolizumab), is a collaboration between Merck and Moderna.

The results from the phase 2b KEYNOTE-942 study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 27.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

After about a five-year follow-up, the combo drug was found to reduce the risk of melanoma recurrence or death by 49% compared to pembrolizumab alone.

The researchers analyzed data from 157 patients with high-risk stage 3 and 4 melanoma whose cancer had been removed via surgery. The participants were split into two groups — one received the combo therapy and the other only received pembrolizumab, according to a press release.

The therapy was found to reduce the risk of melanoma recurrence or death by 49% compared to pembrolizumab alone after a five-year follow-up. (iStock)

The findings revealed that the combination group saw benefits that were “sustained and durable over time.”

Intismeran autogene is designed using mutations identified in a patient’s own tumor, with the intention of teaching the immune system what the cancer looks like so that it can recognize and attack it.

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

According to the researchers, intismeran is “well-tolerated” with a “manageable” safety profile. 

The most commonly cited side effects of the personalized mRNA vaccine plus KEYTRUDA were fatigue, injection-site pain, chills, fever and headache. The researchers reported no new long-term safety concerns and no severe vaccine-related adverse events.

The combination therapy is currently being evaluated in a phase 3 study — the final confirmation stage.

Patients with late-stage melanoma have a “significant risk” of cancer recurrence, according to an expert. (iStock)

Advertisement

In a Merck press release from January, Kyle Holen, MD, Moderna’s senior vice president and head of development, oncology and therapeutics, noted that this data highlights the “potential of a prolonged benefit … in patients with resected high-risk melanoma.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“We continue to invest in our platform in oncology because of encouraging outcomes like these, which illustrate mRNA’s potential in cancer care,” he said.  

Dr. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, also commented that for many patients with stage 3 or 4 melanoma, there is a “significant risk of recurrence following surgery.”

Researchers confirmed that the combination therapy is currently being evaluated in a phase 3 study. (iStock)

Advertisement

“As such, demonstrating the longer-term potential of intismeran autogene and KEYTRUDA to reduce the risk of recurrence for certain patients with melanoma is a meaningful milestone,” she said.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The company cited encouraging five-year follow-up data and pointed to upcoming late-stage INTerpath trial results with Moderna in several hard-to-treat cancers.

Continue Reading

Health

What Really Happens When You Drink Alcohol During a Weight Loss Journey? Experts Explain

Published

on

What Really Happens When You Drink Alcohol During a Weight Loss Journey? Experts Explain


Advertisement





What Happens If You Drink Alcohol on a Weight Loss Journey?




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading
Advertisement

Trending